N
Nicholas A. Meanwell
Researcher at Bristol-Myers Squibb
Publications - 449
Citations - 19569
Nicholas A. Meanwell is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Alkyl & Hepatitis C virus. The author has an hindex of 56, co-authored 426 publications receiving 16399 citations. Previous affiliations of Nicholas A. Meanwell include ViiV Healthcare & University of Sheffield.
Papers
More filters
Journal ArticleDOI
Applications of Fluorine in Medicinal Chemistry
TL;DR: The effects of the strategic incorporation of fluorine in drug molecules and applications in positron emission tomography are provided, as well as new synthetic methodologies that allow more facile access to a wide range of fluorinated compounds.
Journal ArticleDOI
Synopsis of some recent tactical application of bioisosteres in drug design.
TL;DR: In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compound optimization and the long-term success of drug candidates.
Journal ArticleDOI
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
TL;DR: In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a molecule are summarized.
Journal ArticleDOI
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Min Gao,Richard E. Nettles,Makonen Belema,Lawrence B. Snyder,Van N. Nguyen,Robert A. Fridell,Michael H. Serrano-Wu,David R. Langley,Jin-Hua Sun,Donald R. O'Boyle,Julie A. Lemm,Chunfu Wang,Jay O. Knipe,Caly Chien,Richard J. Colonno,Dennis M. Grasela,Nicholas A. Meanwell,Lawrence G. Hamann +17 more
TL;DR: These results provide the first clinical validation of an inhibitor of HCV NS5A, a protein with no known enzymatic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations ofHCV inhibitors.
Journal ArticleDOI
A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design
TL;DR: The role of sulfur interactions in protein structure and function is discussed and although relatively rare, intermolecular interactions between ligand C-S σ* orbitals and proteins are illustrated.